keyword
MENU ▼
Read by QxMD icon Read
search

cetuximab head and neck cancers

keyword
https://www.readbyqxmd.com/read/28054529/a-retrospective-analysis-of-patients-with-head-and-neck-cancer-treated-with-radiation-hyperthermia-and-cetuximab-a-brief-report-of-outcome
#1
Nagraj G Huilgol
PURPOSE: Advanced head and neck cancer continues to have a dismal outcome. Chemoradiation remains the current standard of care. Chemoradiation has not achieved the desired increase in survival in locally advanced head and neck cancer. This is a retrospective analysis of six patients treated with hyperthermia, radiation therapy, and cetuximab. We wished to determine if this combination treatment would further improve the outcome. MATERIALS AND METHODS: Six patients with squamous cell cancer of the head and neck region were treated with hyperthermia, cetuximab, and radiation therapy...
July 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28048906/su-f-t-666-molecular-targeted-gold-nanorods-enhances-the-rbe-of-proton-therapy
#2
A Khoo, N Sahoo, S Krishnan, P Diagaradjane
PURPOSE: In recent years, proton beam radiation therapy (PBRT) has gained significant attention in the treatment of tumors in anatomically complex locations. However, the therapeutic benefit of PBRT is limited by a relative biological effectiveness (RBE) of just 1.1. The purpose of this study is to evaluate whether this limitation can be overcome by artificially enhancing the RBE using molecular-targeted gold nanorods (GNRs). METHODS: Molecular-targeting of GNRs was accomplished using Cetuximab (antibody specific to epidermal growth factor receptor that is over-expressed in tumors) conjugated GNRs (cGNRs) and their binding affinity to Head and Neck cancer cells was confirmed using dark field microscopy and Transmission Electron Microscopy (TEM)...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28043710/complication-and-surgical-site-infection-for-salvage-surgery-in-head-and-neck-cancer-after-chemoradiotherapy-and-bioradiotherapy
#3
Hidenori Suzuki, Nobuhiro Hanai, Daisuke Nishikawa, Yujiro Fukuda, Yasuhisa Hasegawa
OBJECTIVE: We aimed to investigate the complications, surgical site infection (SSI), and survival in salvage surgery without free-flap reconstruction for patients with head and neck squamous cell carcinoma who were treated by platinum-based chemoradiotherapy (Plat-CRT) or cetuximab-based bioradiotherapy (Cet-BRT). METHODS: Thirty-three patients treated by Plat-CRT and six treated by Cet-BRT had salvage surgery. We categorized postoperative complications according to the Clavien-Dindo classification and SSI according to the wound grading scale...
December 30, 2016: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/28042324/mapping-sentinel-lymph-node-metastasis-by-dual-probe-optical-imaging
#4
Xiangyu Yang, Zhe Wang, Fuwu Zhang, Guizhi Zhu, Jibin Song, Gao-Jun Teng, Gang Niu, Xiaoyuan Chen
Purpose: Sentinel lymph node biopsy (SLNB) has emerged as the preferred standard procedure in patients with breast cancer, melanoma and other types of cancer. Herein, we developed a method to intra-operatively map SLNs and differentiate tumor metastases within SLNs at the same time, with the aim to provide more accurate and real-time intraoperative guidance. Experimental Design: Hyaluronic acid (HA), a ligand of lymphatic vessel endothelial hyaluronan receptor (LYVE)-1, is employed as a SLN mapping agent after being conjugated with a near-infrared fluorophore (Cy5...
2017: Theranostics
https://www.readbyqxmd.com/read/28032952/clinical-outcome-of-salvage-neck-dissections-in-head-and-neck-cancer-in-relation-to-initial-treatment-extent-of-surgery-and-patient-factors
#5
Karlijn van den Bovenkamp, Maartje G Noordhuis, Sjoukje F Oosting, Bernard F A M van der Laan, Jan L Roodenburg, Hendrik P Bijl, György B Halmos, Boudewijn E C Plaat
OBJECTIVE: Salvage surgery has a higher complication rate compared to primary surgical treatment. We evaluated clinical outcome of salvage neck dissections in relation to initial treatment modality, extent of surgery, and patient related factors. DESIGN: Single institution consecutive case series. SETTING: Tertiary Head and Neck Cancer Center. PARTICIPANTS: Eighty-seven patients with head and neck squamous cell carcinoma, who underwent salvage neck dissection after initial radiotherapy (n=30), radiotherapy with carboplatin/5-fluorouracil (n=43), or radiotherapy with cetuximab (n=14)...
December 29, 2016: Clinical Otolaryngology
https://www.readbyqxmd.com/read/28031227/cetuximab-resistance-in-head-and-neck-cancer-is-mediated-by-egfr-k521-polymorphism
#6
Friederike Braig, Malte Kriegs, Beate Habel, Minna Voigtlaender, Tobias Grob, Karina Biskup, Véronique Blanchard, Markus Sack, Anja Thalhammer, Isabel Ben Batalla, Ingke Braren, Simon Laban, Antje Danielczyk, Steffen Goletz, Elzbieta Jakubowicz, Bruno Märkl, Martin Trepel, Rainald Knecht, Kristoffer Riecken, Boris Fehse, Sonja Loges, Carsten Bokemeyer, Mascha Binder
Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR targeting drug cetuximab poses a challenge to their effective clinical management. Here we report a specific mechanism of resistance in this setting based upon the presence of a single nucleotide polymorphism encoding EGFR-K521 (K-allele), which is expressed in >40% of HNSCC cases. Patients expressing the K-allele showed significantly shorter progression-free survival upon palliative treatment with cetuximab plus chemotherapy or radiation...
December 28, 2016: Cancer Research
https://www.readbyqxmd.com/read/28012793/pet-imaging-of-zirconium-89-labelled-cetuximab-a-phase-i-trial-in-patients-with-head-and-neck-and-lung-cancer
#7
Judith van Loon, Aniek J G Even, Hugo J W L Aerts, Michel Öllers, Frank Hoebers, Wouter van Elmpt, Ludwig Dubois, Anne-Marie C Dingemans, Roy I Lalisang, Pascal Kempers, Boudewijn Brans, Véronique Winnepenninckx, Ernst-Jan Speel, Eric Thunnissen, Kim M Smits, Ronald Boellaard, Danielle J Vugts, Dirk De Ruysscher, Philippe Lambin
BACKGROUND AND PURPOSE: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)Zr-cetuximab and to assess tumour uptake. METHODS: Two dose schedules were used; two consecutive doses of 60MBq (89)Zr-cetuximab or a single dose of 120MBq, both preceded by 400mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2)...
December 21, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28011050/could-the-addition-of-cetuximab-to-conventional-radiation-therapy-improve-organ-preservation-in-those-patients-with-locally-advanced-larynx-cancer-who-respond-to-induction-chemotherapy-an-organ-preservation-spanish-head-and-neck-cancer-cooperative-group-phase
#8
Ricard Mesía, Jose A Garcia-Saenz, Alicia Lozano, Miguel Pastor, Juan J Grau, Javier Martínez-Trufero, Julio Lambeaz, Joaquina Martínez-Galán, Jose R Mel, Belen González, Silvia Vázquez, Manel Mañós, Miren Taberna, Beatriz Cirauqui, Elvira Del Barco, Esther Casado, Jordi Rubió-Casadevall, Angles Rodríguez-Jaráiz, Juan J Cruz
PURPOSE: To evaluate the efficacy and safety of induction chemotherapy (IC) followed by bioradiotherapy (BRT) to achieve functional larynx preservation in the setting of locally advanced head and neck tumors. METHODS AND MATERIALS: This was a phase 2, open-label, multicenter study of patients with stage III and IVA laryngeal carcinoma who were candidates for total laryngectomy. The primary endpoint was the rate of survival with functional larynx (SFL) at 3 years, with a critical value to consider the study positive of SFL >59%...
November 17, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28006061/the-kras-variant-as-a-predictive-biomarker-of-cetuximab-response-in-head-and-neck-cancer
#9
Jeffrey P Bruce, Wei Xu, Fei-Fei Liu
No abstract text is available yet for this article.
December 22, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28006059/the-kras-variant-and-cetuximab-response-in-head-and-neck-squamous-cell-cancer-a-secondary-analysis-of-a-randomized-clinical-trial
#10
Joanne B Weidhaas, Jonathan Harris, Dörthe Schaue, Allen M Chen, Robert Chin, Rita Axelrod, Adel K El-Naggar, Anurag K Singh, Thomas J Galloway, David Raben, Dian Wang, Chance Matthiesen, Vilija N Avizonis, Rafael R Manon, Omar Yumen, Phuc Felix Nguyen-Tan, Andy Trotti, Heath Skinner, Qiang Zhang, Robert L Ferris, David Sidransky, Christine H Chung
Importance: There is a significant need to find biomarkers of response to radiotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that predict altered immunity, thereby enabling personalized treatment. Objectives: To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)-variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker of cetuximab response and altered immunity in the setting of radiotherapy and cisplatin treatment and to evaluate the interaction of the KRAS-variant with p16 status and blood-based transforming growth factor β1 (TGF-β1)...
December 22, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27997054/stereotactic-body-radiotherapy-for-recurrent-head-and-neck-cancer-a-critical-review
#11
REVIEW
Sujith Baliga, Rafi Kabarriti, Nitin Ohri, Hilda Haynes-Lewis, Ravindra Yaparpalvi, Shalom Kalnicki, Madhur K Garg
The management of patients with recurrent head and neck cancers remains a challenging clinical dilemma. Concerns over toxicity with re-irradiation have limited its use in the clinical setting. Stereotactic Body Radiation Therapy (SBRT) has emerged as a highly conformal and precise type of radiotherapy and has the advantage of sparing normal tissue. Although SBRT is an attractive treatment modality, its use in the clinic is limited, given the technically challenging nature of the procedure. In this review, we attempt to provide a comprehensive overview of the role of re-irradiation in patients with recurrent head and neck cancers, with particular attention to the advent of SBRT and its use with systemic therapies such as cetuximab...
December 20, 2016: Head & Neck
https://www.readbyqxmd.com/read/27994592/kir-genes-and-their-ligands-predict-the-response-to-anti-egfr-monoclonal-antibodies-in-solid-tumors
#12
Cristina Morales-Estevez, Juan De la Haba-Rodriguez, Barbara Manzanares-Martin, Ignacio Porras-Quintela, Antonio Rodriguez-Ariza, Alberto Moreno-Vega, Maria J Ortiz-Morales, Maria A Gomez-España, Maria T Cano-Osuna, Javier Lopez-Gonzalez, Beatriz Chia-Delgado, Rafael Gonzalez-Fernandez, Enrique Aranda-Aguilar
Killer-cell immunoglobulin-like receptors (KIRs) regulate the killing function of natural killer cells, which play an important role in the antibody-dependent cell-mediated cytotoxicity response exerted by therapeutic monoclonal antibodies (mAbs). However, it is unknown whether the extensive genetic variability of KIR genes and/or their human leukocyte antigen (HLA) ligands might influence the response to these treatments. This study aimed to explore whether the variability in KIR/HLA genes may be associated with the variable response observed to mAbs based anti-epidermal growth factor receptor (EGFR) therapies...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27986347/subgroup-analysis-according-to-human-papillomavirus-status-and-tumor-site-of-a-randomized-phase-ii-trial-comparing-cetuximab-and-cisplatin-combined-with-radiation-therapy-for-locally-advanced-head-and-neck-cancer
#13
Michela Buglione, Marta Maddalo, Renzo Corvò, Luigi Pirtoli, Fabiola Paiar, Luciana Lastrucci, Marco Stefanacci, Liliana Belgioia, Monica Crociani, Stefania Vecchio, Pierluigi Bonomo, Silvia Bertocci, Paolo Borghetti, Nadia Pasinetti, Luca Triggiani, Loredana Costa, Sandro Tonoli, Salvatore Grisanti, Stefano Maria Magrini
PURPOSE: We report a subgroup analysis primarily focused on human papillomavirus (HPV)-related oropharyngeal cancer (OPC) from the Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT; ClinicalTrials.gov identifier NCT01216020) trial comparing radiation therapy with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced head and neck cancer. METHODS AND MATERIALS: The data from all the patients in the CTXMAB+RT trial were reviewed and separately analyzed in 3 groups: p16-positive OPC, p16-negative OPC, and all other cancer sites...
October 20, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27980104/the-fa-brca-pathway-identified-as-the-major-predictor-of-cisplatin-response-in-head-and-neck-cancer-by-functional-genomics
#14
Sanne R Martens-de Kemp, Arjen Brink, Ida H van der Meulen, Renee X De Menezes, Dennis E Te Beest, C Rene Leemans, Victor W van Beusechem, Boudewijn J M Braakhuis, Ruud H Brakenhoff
Patients with advanced stage head and neck squamous cell carcinoma (HNSCC) are often treated with cisplatin-containing chemoradiation protocols. Although cisplatin is an effective radiation sensitizer, it causes severe toxicity and not all patients benefit from the combination treatment. HNSCCs expectantly not responding to cisplatin may better be treated with surgery and postoperative radiation or cetuximab and radiation, but biomarkers to personalize chemoradiotherapy, are not available. We performed an unbiased genome-wide functional genetic screen in vitro to identify genes that influence the response to cisplatin in HNSCC cells...
December 15, 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27965472/quantitative-assessment-of-zirconium-89-labeled-cetuximab-using-pet-ct-imaging-in-patients-with-advanced-head-and-neck-cancer-a-theragnostic-approach
#15
Aniek J G Even, Olga Hamming-Vrieze, Wouter van Elmpt, Véronique J L Winnepenninckx, Jolien Heukelom, Margot E T Tesselaar, Wouter V Vogel, Ann Hoeben, Catharina M L Zegers, Daniëlle J Vugts, Guus A M S van Dongen, Harry Bartelink, Felix M Mottaghy, Frank Hoebers, Philippe Lambin
Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced head and neck squamous cell carcinomas (LAHNSCC) are lacking. We hypothesize that tumor accessibility is an important factor in treatment success of the EGFR targeting drug. We quantified uptake of cetuximab labeled with Zirconium-89 (89Zr) using PET/CT imaging.Seventeen patients with stage III-IV LAHNSCC received a loading dose unlabeled cetuximab, followed by 10 mg 54.5±9.6 MBq 89Zr-cetuximab. PET/CT images were acquired either 3 and 6 or 4 and 7 days post-injection...
December 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27959944/bemer-electromagnetic-field-therapy-reduces-cancer-cell-radioresistance-by-enhanced-ros-formation-and-induced-dna-damage
#16
Katja Storch, Ellen Dickreuter, Anna Artati, Jerzy Adamski, Nils Cordes
Each year more than 450,000 Germans are expected to be diagnosed with cancer subsequently receiving standard multimodal therapies including surgery, chemotherapy and radiotherapy. On top, molecular-targeted agents are increasingly administered. Owing to intrinsic and acquired resistance to these therapeutic approaches, both the better molecular understanding of tumor biology and the consideration of alternative and complementary therapeutic support are warranted and open up broader and novel possibilities for therapy personalization...
2016: PloS One
https://www.readbyqxmd.com/read/27938999/overcoming-radioresistance-in-head-and-neck-squamous-cell-carcinoma
#17
REVIEW
Vicky N Yamamoto, David S Thylur, Michael Bauschard, Isaac Schmale, Uttam K Sinha
Radiation therapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet therapeutic efficacy is hindered by treatment-associated toxicity and tumor recurrence. In comparison to other cancers, innovation has proved challenging, with the epidermal growth factor receptor (EGFR) antibody cetuximab being the only new radiosensitizing agent approved by the FDA in over half a century. This review examines the physiological mechanisms that contribute to radioresistance in HNSCC as well as preclinical and clinical data regarding novel radiosensitizing agents, with an emphasis on those with highest translational promise...
December 2016: Oral Oncology
https://www.readbyqxmd.com/read/27938998/epidermal-growth-factor-receptor-egfr-pathway-polymorphisms-as-predictive-markers-of-cetuximab-toxicity-in-locally-advanced-head-and-neck-squamous-cell-carcinoma-hnscc-in-a-spanish-population
#18
J Fernández-Mateos, R Seijas-Tamayo, R Mesía, M Taberna, M Pastor Borgoñón, E Pérez-Ruiz, J C Adansa Klain, S Vázquez Fernández, E Del Barco Morillo, A Lozano, R González Sarmiento, J J Cruz-Hernández
OBJECTIVES: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab. MATERIAL AND METHODS: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013...
December 2016: Oral Oncology
https://www.readbyqxmd.com/read/27892728/a-phase-i-ii-study-of-nab-paclitaxel-cisplatin-and-cetuximab-with-concurrent-radiation-therapy-for-locally-advanced-squamous-cell-cancer-of-the-head-and-neck
#19
Stephen G Chun, Randall Hughes, Baran D Sumer, Larry L Myers, John M Truelson, Saad A Khan, Tsung-Wei Ma, Yang Xie, John S Yordy, Susan Cooley, Jean Wu, Hak Choy, Lucien A Nedzi
Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m(2) with 20 mg/m(2) cisplatin and 250 mg/m(2) cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0...
November 28, 2016: Cancer Investigation
https://www.readbyqxmd.com/read/27880014/inhibition-of-epithelial-mesenchymal-transition-by-cetuximab-via-the-egfr-gep100-arf6-amap1-pathway-in-head-and-neck-cancer
#20
Yoshifumi Matsumoto, Hiroyuki Sakurai, Yasunao Kogashiwa, Toru Kimura, Yuma Matsumoto, Takashi Shionome, Masatake Asano, Koichiro Saito, Naoyuki Kohno
BACKGROUND: Despite improved survival by the addition of a monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, to chemotherapy or radiotherapy for squamous cell carcinoma of the head and neck (SCCHN), cetuximab by itself is not a potent antiproliferative agent against SCCHN. We aimed to elucidate working mechanism of cetuximab in SCCHN. METHODS: The effect of cetuximab on the proliferation, migration, invasion, epithelial-mesenchymal transition, and signaling events downstream of the EGFR were investigated in 4 SCCHN cell lines...
November 23, 2016: Head & Neck
keyword
keyword
54952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"